Castle Biosciences INC 8-K filings

Castle Biosciences reported strong second quarter 2026 results, with revenue increasing to $103.5 million and full-year revenue guidance raised to $365-375 million.

Castle Biosciences stockholders re-elected three Class I directors and ratified the appointment of KPMG LLP as the independent auditor.

Castle Biosciences reported first quarter 2026 results, with revenue of $83.7 million and an increase in total test reports for core drivers by 36%, leading to an upward revision of full-year revenue guidance.

Castle Biosciences reported strong fourth quarter and full-year 2025 results, exceeding revenue guidance with $344 million and significant growth in core test reports.

Castle Biosciences announced preliminary unaudited Q4 and full-year 2025 results, with total revenue exceeding $340 million, above previous guidance, driven by strong growth in core diagnostic tests.

Castle Biosciences reported mixed third-quarter 2025 financial results, including a revenue decline, but raised its full-year 2025 revenue guidance and launched a new atopic dermatitis test.

Castle Biosciences, Inc. adopted amended bylaws, enhancing board authority over meetings and nominations while increasing shareholder proposal requirements.

Castle Biosciences reported strong Q2 2025 core test volume growth and raised its full-year revenue guidance, despite a slight dip in overall Q2 revenue and profitability metrics.

Castle Biosciences, Inc. announced that its stockholders approved an amendment to the company's Certificate of Incorporation to exculpate officers from monetary liability and re-elected three Class III directors at its 2025 Annual Meeting.

Castle Biosciences announces a 21% increase in Q1 2025 revenue, driven by core test growth, and raises its full-year 2025 revenue guidance.

Castle Biosciences announces a 51% increase in full-year 2024 revenue, reaching $332 million, and a 36% increase in total test reports delivered.

Castle Biosciences expects to meet or exceed the top end of its full-year 2024 revenue guidance, driven by a significant increase in total test reports delivered.

Castle Biosciences announced a 39% increase in third-quarter revenue compared to the same period last year, along with a significant increase in total test reports delivered and raised its full-year revenue guidance.

Castle Biosciences announced a 74% increase in revenue and a 49% increase in total test reports for the second quarter of 2024, along with raising its full-year revenue guidance.

Castle Biosciences held its 2024 annual meeting of stockholders, where key proposals including the election of directors and ratification of the accounting firm were approved.

Castle Biosciences announced a 74% increase in revenue and a 40% increase in total test reports for the first quarter of 2024, leading to an increased full-year revenue guidance.

Castle Biosciences has entered into a loan agreement for up to $35 million to fund a new headquarters and working capital, while also adding Rodney Cotton to its board of directors.

Castle Biosciences announced a 60% increase in revenue for 2023, reaching $220 million, driven by strong test report volume growth and consistent execution.